• Neurocrine Biosciences director George J. Morrow sold 15,000 common shares from Oct. 30 through Nov. 3, 2026.
• During the same period, Morrow exercised non-qualified stock options for 15,000 common shares at $53.64 per share.
• His direct common stock holdings remained at 10,386 shares following the transactions; no options from the reported grant remained.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001068754-26-000009), on November 03, 2026, and is solely responsible for the information contained therein.